Efficacy of 223Radium in radioactive iodine refractory bone metastases from thyroid cancer: Preliminary results of a single arm Phase II trial

Conclusions: The trial was stopped after the first step analysis for absence of response to Radium 223 according to PERCIST criteria at FDG PET in patients with bone metastases from RAI refractory DTC. Furthermore awareness of hematological toxicity in case of previously RAI and external radiation therapy is needed.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Deandreis, D., Maillard, A., Borget, I., Zerdoud, S., Bournaud, C., Leenhardt, L., Terroir, M., Al Ghuzlan, A., Schlumberger, M., Leboulleux, S. Tags: Therapy Concepts I: Endocrinology Source Type: research